Effect of Human Concentration Nucleoside Transporters 1 and Multi-drug Resistance Protein 4 Gene Polymorphism on Response of Chronic Hepatitis B to Nucleoside Analogues Treatment

WANG Wen-zhen, LU Li-xia, LI Da-jiang. et al

Abstract

To investigate the effect of human concentration nucleoside transporters 1(hCNT1/SLC28A1) and multi-drug resistance protein 4(MRP4/ABCC4) gene polymorphism on the response of chronic hepatitis B patients to nucleoside analogues treatment. Methods There were 136 patients of chronic hepatitis B treated with entecavir (68) or telbivudine (68). The allele and gene frequency distributing of the four loci of hCNT1/SLC28A1 and MRP4/ABCC4 as well as the polymorphisms were detected in all patients by multiplex snapshot single base extension method. Based on the treatment response, the patients were divided into primary partial response (PPR) group and complete viral response (CVR) group, hCNT1/SLC28A1 and MRP4/ABCC4 gene polymorphism between these two groups were analyzed. Results The rates of PPR and CVR were 56.6% (77/136) and 43.4% (59/136) respectively. There was no statistical difference in baseline HBV DNA value, hepatitis B virus genotype and HBeAg status between PPR and CVR groups (P=0.148, P=0.622,P=0.071) .The distribution of allelotype rs2290272 C/T and rs11568658 G/G in PPR group were higher than those in CVR [CM(155mm]group (P=0.043, P=0.049). Haplotype of C/A/T/C and C/C/G/G in CVR group were higher than those in PPR group (P=0.024,P=0.005). Conclusion The single nucleotide polymorphisms (SNPs) of two candidate genes, including rs2290272 C/T of hCNT1/SLC28A1 and rs11568658 G/G of MRP4/ABCC4, may weak the response of chronic hepatitis B to nucleoside analogues treatment, as well as haplotype of C/A/T/C and C/C/G/G may enhance the response.

 

Keywords: Chronic hepatitis B, Nucleoside analogues, Human concentration nucleoside transporters1 (hCNT1/SLC28A1), Multi-drug resistance protein 4 (MRP4/ABCC4), Single nucleotide polymorphism (SNP) 

 

Full Text:

PDF


References


European Association for the Study of the Liver. EASL clinical practice guidelines; management of chronic hepatitis В virus infection. J Hepatol.2012;57( 1): 167-185.

Lok AS, McMahon BJ. Chronic hepatitis B; update 2009. Hepatology,2009; 50( 3);661-662.

Liaw YF. Kao J H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B; a 2012 update. Hepatol Int,2012;6(4) :531-561.

Uemura T, Oguri T, Ozasa H. et al. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010; 101 (11):2404-2410.

Ren S, Yu H. Zhang H, et al. Polymorphisms of interferon- inducible genes GAS associated with interferon-a treatment response in chronic HBV infection. Antiviral Res,2011;89(3) : 232-237.

Mizokami M. Discovery of critical host factor, IL-28B, associated with response to hepatitis С virus treatment. J Gastroen Hepatol,2012;27(3): 425-429.

Minuesa G, Huber-Ruano I. Pastor-Anglada M« et al. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther. 2011;132(3):268-279.

Keeffe EB.Marcellin P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol.2007;5(3) :285-294.

Chang TT,Gish RCj.de Man R.et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New Engl J Med.2006;354(10): 1001-1010.

Lai CL.Shouval D.Lok AS,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New Engl J Med.2006;354(10):1011-1020.

Liaw YF.Gane E.Leung N,et al. 2-year GLOBE trial results; telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology,2009 ; 136(2) :486-495.

lloeje LUH. Yang HI. Su J. et al. Predicting cirrhosis risk based on the level of circulating hepatitis В viral load. Gastroenterology. 2006 ; 130(3) : 678-686.

Ming C, Chun CC. Ming LS,et al. Viral load, genotypes, and mutants in hepatitis В birus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci,2012;57( 1):232-238.

Pawlotsky JM. Dusheiko G. Hatzakis А, et al. Virologic monitoring of hepatitis В virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology,2008; 134(2);405-415.

Jardi R. Rodriguez-Frias F. Schaper M. et al. Analysis of hepatitis В genotype changes in chronic hepatitis В infection; influence of antiviral therapy. J Hepatol.2008;49 (5) : 695-701.

Cooksley WO. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat, 2010; 17 ( 9 ); 601- 610.


Refbacks

  • There are currently no refbacks.